title: Nonhuman primate models for Epstein-Barr virus infection.
abstract: Epstein-Barr virus (EBV) is a human herpesvirus that infects nearly all humans by adulthood and is associated with a spectrum of human diseases including Infectious Mononucleosis, Hodgkin Lymphoma, Nasopharyngeal Carcinoma, and lymphomas in immunosuppressed hosts. Nonhuman primate (NHP) animal models provide important experimental systems for studying EBV infection. There has been significant progress in studies of EBV-related herpesviruses, or lymphocryptoviruses (LCV), that naturally infect New and Old World NHPs. Prototypes for New and Old World LCV have been cloned and sequenced, humoral and cellular immune responses to LCV in NHP have been characterized, experimental LCV infections in naïve rhesus macaques have been successful, and a genetic system to manipulate specific viral genes in rhesus LCV (rhLCV) has been developed. These advances have led to new insights in the dynamic interactions with the host during acute and persistent EBV infection and can provide a novel platform for EBV vaccine development. Further development and utilization of the rhLCV animal model would be greatly enhanced by expansion of LCV-free breeding colonies as a reliable source of naïve animals for experimental studies. NHP animal models for EBV infection provide unique opportunities for understanding the biology of EBV infection in humans and translating that knowledge into effective vaccines against EBV-induced diseases.
authors.affiliation: Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, MCP 836, 181 Longwood Avenue, Boston, MA 02115, United States. fwang@rics.bwh.harvard.edu
authors.forename: Fred
authors.initials: F
authors.lastname: Wang
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000473:pathology* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000472:pathogenicity*; D054884:Host-Pathogen Interactions; D008253:Macaca mulatta
references.citation: Nature. 1985 Nov 21-27;318(6043):287-9
references.pmid: 2999604
references.citation: Comp Med. 2000 Feb;50(1):59-68
references.pmid: 10987671
references.citation: J Infect Dis. 2007 Dec 15;196(12):1749-53
references.pmid: 18190254
references.citation: J Virol. 2000 Jan;74(1):379-89
references.pmid: 10590127
references.citation: PLoS Pathog. 2012 Dec;8(12):e1003095
references.pmid: 23300447
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1224-9
references.pmid: 11158621
references.citation: J Virol. 1995 Dec;69(12):8011-9
references.pmid: 7494314
references.citation: J Virol. 2011 Feb;85(3):1330-9
references.pmid: 21084476
references.citation: Blood. 2004 Sep 1;104(5):1482-9
references.pmid: 15150077
references.citation: J Virol. 2005 Aug;79(15):10069-72
references.pmid: 16014968
references.citation: J Virol. 2003 Oct;77(19):10695-9
references.pmid: 12970457
references.citation: J Virol. 2002 Dec;76(23):12055-68
references.pmid: 12414947
references.citation: J Exp Med. 1977 Apr 1;145(4):948-67
references.pmid: 192829
references.citation: J Virol. 1996 Nov;70(11):7819-26
references.pmid: 8892903
references.citation: J Virol. 2011 Jan;85(1):165-77
references.pmid: 20980506
references.citation: J Virol. 1998 Apr;72(4):3205-12
references.pmid: 9525646
references.citation: Int J Cancer. 1986 Sep 15;38(3):425-32
references.pmid: 3017870
references.citation: Science. 1997 Jun 27;276(5321):2030-3
references.pmid: 9197263
references.citation: J Virol. 1999 Sep;73(9):7381-9
references.pmid: 10438828
references.citation: J Virol. 2002 Jan;76(1):421-6
references.pmid: 11739708
references.citation: PLoS Pathog. 2011 Oct;7(10):e1002308
references.pmid: 22028652